Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
Mohammud M Alam, Saborny Mahmud, Sandeep Aggarwal, Sawsan Fathma, Naim Al Mahi, Mohammed S Shibli, Siddiqi M Haque, Sharothy Mahmud, Ziauddin Ahmed
Cureus, doi:10.7759/cureus.14933
Importance Coronavirus disease 2019 (COVID-19) outbreaks are frequent occurrences in nursing homes and long-term care facilities (LTCFs), resulting in subsequent hospitalization and death.
Rationale Virus-neutralizing monoclonal antibodies demonstrate a significant decrease in both viral load and hospital transfer rate among patients with mild-to-moderate COVID-19 infection.
Objective To assess the clinical outcomes of COVID-19 patients with mild-to-moderate symptoms in LTCFs who received LY-CoV555 as compared to those who did not receive this treatment.
Design Retrospective case-control study and logistic regression analysis.
Setting LTCFs in New York.
Participants Two-hundred forty-six (246) LTCF patients diagnosed with mild-to-moderate COVID-19 infection with positive COVID-19 polymerase chain reaction (PCR) from November 15, 2020, to January 31, 2021.
Methods Two-hundred forty-six (246) COVID-19 patients were identified from electronic medical records, out of which 160 cases were exposed to LY-CoV555 treatment (700 mg single dose, intravenous infusion). Eightysix (86) patients were unexposed controls who did not receive monoclonal antibodies, LY-CoV555.
Outcome We assessed the odds of death and hospitalization of exposed cases as compared to unexposed controls. Using logistic regression analysis, we also assessed the risk factors associated with these outcomes in the entire sample population.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Regeneron, None
{ 'indexed': {'date-parts': [[2024, 2, 10]], 'date-time': '2024-02-10T00:06:12Z', 'timestamp': 1707523572364},
'reference-count': 30,
'publisher': 'Springer Science and Business Media LLC',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2021, 5, 10]]},
'DOI': '10.7759/cureus.14933',
'type': 'journal-article',
'created': {'date-parts': [[2021, 5, 10]], 'date-time': '2021-05-10T15:18:59Z', 'timestamp': 1620659939000},
'source': 'Crossref',
'is-referenced-by-count': 5,
'title': 'Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality '
'and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study',
'prefix': '10.7759',
'author': [ {'given': 'Mohammud M', 'family': 'Alam', 'sequence': 'first', 'affiliation': []},
{'given': 'Saborny', 'family': 'Mahmud', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sandeep', 'family': 'Aggarwal', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sawsan', 'family': 'Fathma', 'sequence': 'additional', 'affiliation': []},
{'given': 'Naim', 'family': 'Al Mahi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mohammed S', 'family': 'Shibli', 'sequence': 'additional', 'affiliation': []},
{'given': 'Siddiqi M', 'family': 'Haque', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sharothy', 'family': 'Mahmud', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ziauddin', 'family': 'Ahmed', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'reference': [ { 'key': 'ref1',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMe2002387',
'article-title': 'Covid-19 - navigating the uncharted',
'volume': '382',
'author': 'Fauci AS',
'year': '2020',
'unstructured': 'Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted. N '
'Engl J Med. 2020, 382:1268-9. 10.1056/NEJMe2002387',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref2',
'unstructured': 'COVID-19 dashboard by the Center for Systems Science and Engineering '
'(CSSE) at Johns Hopkins University. (2020). Accessed. April 5, 2021: '
'https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.'},
{ 'key': 'ref3',
'unstructured': 'The New York Times. How many of these 68,000 deaths could have been '
'avoided?. (2020). '
'https.//www.nytimes.com/2020/09/05/opinion/sunday/coronavirus-nursing-homes-deaths.html.'},
{ 'key': 'ref4',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2020.8857',
'article-title': 'Effect of high vs low doses of chloroquine diphosphate as adjunctive '
'therapy for patients hospitalized with severe acute respiratory '
'syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical '
'trial',
'volume': '3',
'author': 'Borba MGS',
'year': '2020',
'unstructured': 'Borba MGS, Val FFA, Sampaio VS, et al.. Effect of high vs low doses of '
'chloroquine diphosphate as adjunctive therapy for patients hospitalized '
'with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) '
'infection: a randomized clinical trial. JAMA Netw Open. 2020, 3:e208857. '
'10.1001/jamanetworkopen.2020.8857',
'journal-title': 'JAMA Netw Open'},
{ 'key': 'ref5',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2020.16349',
'article-title': 'Effect of remdesivir vs standard care on clinical status at 11 days in '
'patients with moderate COVID-19. A randomized clinical trial',
'volume': '324',
'author': 'Spinner CD',
'year': '2020',
'unstructured': 'Spinner CD, Gottlieb RL, Criner GJ, et al.. Effect of remdesivir vs '
'standard care on clinical status at 11 days in patients with moderate '
'COVID-19. A randomized clinical trial. JAMA. 2020, 324:1048-57. '
'10.1001/jama.2020.16349',
'journal-title': 'JAMA'},
{ 'key': 'ref6',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijid.2020.11.191',
'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may '
'reduce the duration of illness',
'volume': '103',
'author': 'Ahmed S',
'year': '2021',
'unstructured': 'Ahmed S, Karim MM, Ross AG, et al.. A five-day course of ivermectin for '
'the treatment of COVID-19 may reduce the duration of illness. Int J '
'Infect Dis. 2021, 103:214-6. 10.1016/j.ijid.2020.11.191',
'journal-title': 'Int J Infect Dis'},
{ 'key': 'ref7',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.08.27.20183442',
'article-title': 'Tocilizumab in hospitalized patients with COVID-19 pneumonia [Preprint]',
'author': 'Rosas IO',
'year': '2020',
'unstructured': 'Rosas IO, Bräu N, Waters M, et al.. Tocilizumab in hospitalized patients '
'with COVID-19 pneumonia [Preprint]. MedRxiv. 2020, '
'10.1101/2020.08.27.20183442',
'journal-title': 'MedRxiv'},
{ 'key': 'ref8',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(20)30361-5',
'article-title': 'On the use of corticosteroids for 2019-nCoV pneumonia',
'volume': '395',
'author': 'Shang L',
'year': '2020',
'unstructured': 'Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for '
'2019-nCoV pneumonia. Lancet. 2020, 395:683-4. '
'10.1016/S0140-6736(20)30361-5',
'journal-title': 'Lancet'},
{ 'key': 'ref9',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2020.10044',
'article-title': 'Effect of convalescent plasma therapy on time to clinical improvement '
'in patients with severe and life-threatening COVID-19: a randomized '
'clinical trial',
'volume': '324',
'author': 'Li L',
'year': '2020',
'unstructured': 'Li L, Zhang W, Hu Y, et al.. Effect of convalescent plasma therapy on '
'time to clinical improvement in patients with severe and '
'life-threatening COVID-19: a randomized clinical trial. JAMA. 2020, '
'324:460-7. 10.1001/jama.2020.10044',
'journal-title': 'JAMA'},
{ 'key': 'ref10',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.05.18.20066902',
'article-title': 'Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 '
'patients: experience from case series of 54 patients in long-term care '
'facilities [Preprint]',
'author': 'Ahmad I',
'year': '2020',
'unstructured': 'Ahmad I, Alam M, Saadi R, et al.. Doxycycline and hydroxychloroquine as '
'treatment for high-risk COVID-19 patients: experience from case series '
'of 54 patients in long-term care facilities [Preprint]. MedRxiv. 2020, '
'10.1101/2020.05.18.20066902',
'journal-title': 'MedRxiv'},
{ 'key': 'ref11',
'doi-asserted-by': 'publisher',
'DOI': '10.7759/cureus.9658',
'article-title': 'Clinical outcomes of early treatment with doxycycline for 89 high-risk '
'COVID-19 patients in long-term care facilities in New York',
'volume': '12',
'author': 'Alam MM',
'year': '2020',
'unstructured': 'Alam MM, Mahmud S, Rahman MM, Simpson J, Aggarwal S, Ahmed Z. Clinical '
'outcomes of early treatment with doxycycline for 89 high-risk COVID-19 '
'patients in long-term care facilities in New York. Cureus. 2020, '
'12:e9658. 10.7759/cureus.9658',
'journal-title': 'Cureus'},
{ 'key': 'ref12',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.cell.2020.02.052',
'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a '
'clinically proven protease inhibitor',
'volume': '181',
'author': 'Hoffmann M',
'year': '2020',
'unstructured': 'Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry '
'depends on ACE2 and TMPRSS2 and is blocked by a clinically proven '
'protease inhibitor. Cell. 2020, 181:271-280.e8. '
'10.1016/j.cell.2020.02.052',
'journal-title': 'Cell'},
{ 'key': 'ref13',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/science.abd0827',
'article-title': 'Studies in humanized mice and convalescent humans yield a SARS-CoV-2 '
'antibody cocktail',
'volume': '369',
'author': 'Hansen J',
'year': '2020',
'unstructured': 'Hansen J, Baum A, Pascal KE, et al.. Studies in humanized mice and '
'convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020, '
'369:1010-4. 10.1126/science.abd0827',
'journal-title': 'Science'},
{ 'key': 'ref14',
'unstructured': 'Regeneron. (2020). '
'https.//investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-....'},
{ 'key': 'ref15',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2029849',
'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19',
'volume': '384',
'author': 'Chen P',
'year': '2021',
'unstructured': 'Chen P, Nirula A, Heller B, et al.. SARS-CoV-2 neutralizing antibody '
'LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021, 384:229-37. '
'10.1056/NEJMoa2029849',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref16',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2035002',
'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with '
'Covid-19',
'volume': '384',
'author': 'Weinreich DM',
'year': '2021',
'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, et al.. REGN-COV2, a '
'neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J '
'Med. 2021, 384:238-51. 10.1056/NEJMoa2035002',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref17',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.immuni.2020.05.002',
'article-title': 'Immunology of COVID-19: current state of the science',
'volume': '52',
'author': 'Vabret N',
'year': '2020',
'unstructured': 'Vabret N, Britton GJ, Gruber C, et al.. Immunology of COVID-19: current '
'state of the science. Immunity. 2020, 52:910-41. '
'10.1016/j.immuni.2020.05.002',
'journal-title': 'Immunity'},
{ 'key': 'ref18',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/nsr/nwaa041',
'article-title': 'Pathogenic T cells and inflammatory monocytes incite inflammatory storm '
'in severe COVID-19 patients',
'volume': '7',
'author': 'Zhou Y',
'year': '2020',
'unstructured': 'Zhou Y, Fu B, Zheng X, et al.. Pathogenic T cells and inflammatory '
'monocytes incite inflammatory storm in severe COVID-19 patients. Natl '
'Sci Rev. 2020, 7:nwaa041. 10.1093/nsr/nwaa041',
'journal-title': 'Natl Sci Rev'},
{ 'key': 'ref19',
'doi-asserted-by': 'publisher',
'DOI': '10.23812/CONTI-E',
'article-title': 'Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung '
'inflammation by coronavirus-19 (COV-19 or SARS-CoV-2): '
'anti-inflammatory strategies',
'volume': '34',
'author': 'Conti P',
'year': '2020',
'unstructured': 'Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. '
'Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung '
'inflammation by coronavirus-19 (COV-19 or SARS-CoV-2): anti-inflammatory '
'strategies. J Biol Regul Homeost Agents. 2020, 34:327-31. '
'10.23812/CONTI-E',
'journal-title': 'J Biol Regul Homeost Agents'},
{ 'key': 'ref20',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S2352-3026(20)30145-9',
'article-title': 'Coagulation abnormalities and thrombosis in patients with COVID-19',
'volume': '7',
'author': 'Levi M',
'year': '2020',
'unstructured': 'Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and '
'thrombosis in patients with COVID-19. Lancet Haematol. 2020, 7:e438-40. '
'10.1016/S2352-3026(20)30145-9',
'journal-title': 'Lancet Haematol'},
{ 'key': 'ref21',
'doi-asserted-by': 'publisher',
'DOI': '10.1111/jth.14768',
'article-title': 'Abnormal coagulation parameters are associated with poor prognosis in '
'patients with novel coronavirus pneumonia',
'volume': '18',
'author': 'Tang N',
'year': '2020',
'unstructured': 'Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are '
'associated with poor prognosis in patients with novel coronavirus '
'pneumonia. J Thromb Haemost. 2020, 18:844-7. 10.1111/jth.14768',
'journal-title': 'J Thromb Haemost'},
{ 'key': 'ref22',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2028436',
'article-title': 'Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older '
'adults',
'volume': '383',
'author': 'Anderson EJ',
'year': '2020',
'unstructured': 'Anderson EJ, Rouphael NG, Widge AT, et al.. Safety and immunogenicity of '
'SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020, '
'383:2427-38. 10.1056/NEJMoa2028436',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref23',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2101765',
'article-title': 'BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting',
'volume': '384',
'author': 'Dagan N',
'year': '2021',
'unstructured': 'Dagan N, Barda N, Kepten E, et al.. BNT162b2 mRNA Covid-19 vaccine in a '
'nationwide mass vaccination setting. N Engl J Med. 2021, 384:1412-23. '
'10.1056/NEJMoa2101765',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref24',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/cid/ciaa1548',
'article-title': 'Convalescent plasma for patients with severe COVID-19: a matched cohort '
'study',
'author': 'Rogers R',
'year': '2020',
'unstructured': 'Rogers R, Shehadeh F, Mylona EK, et al.. Convalescent plasma for '
'patients with severe COVID-19: a matched cohort study. Clin Infect Dis. '
'2020, ciaa1548. 10.1093/cid/ciaa1548',
'journal-title': 'Clin Infect Dis'},
{ 'key': 'ref25',
'doi-asserted-by': 'publisher',
'DOI': '10.1073/pnas.2004168117',
'article-title': 'Effectiveness of convalescent plasma therapy in severe COVID-19 '
'patients',
'volume': '117',
'author': 'Duan K',
'year': '2020',
'unstructured': 'Duan K, Liu B, Li C, et al.. Effectiveness of convalescent plasma '
'therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020, '
'117:9490-6. 10.1073/pnas.2004168117',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'key': 'ref26',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2031893',
'article-title': 'Convalescent plasma antibody levels and the risk of death from Covid-19',
'volume': '384',
'author': 'Joyner MJ',
'year': '2021',
'unstructured': 'Joyner MJ, Carter RE, Senefeld JW, et al.. Convalescent plasma antibody '
'levels and the risk of death from Covid-19. N Engl J Med. 2021, '
'384:1015-27. 10.1056/NEJMoa2031893',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref27',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-020-2349-y',
'article-title': 'Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV '
'antibody',
'volume': '583',
'author': 'Pinto D',
'year': '2020',
'unstructured': 'Pinto D, Park YJ, Beltramello M, et al.. Cross-neutralization of '
'SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020, '
'583:290-5. 10.1038/s41586-020-2349-y',
'journal-title': 'Nature'},
{ 'key': 'ref28',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2020.10245',
'article-title': 'Monoclonal antibodies for prevention and treatment of COVID-19',
'volume': '324',
'author': 'Marovich M',
'year': '2020',
'unstructured': 'Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention '
'and treatment of COVID-19. JAMA. 2020, 324:131-2. '
'10.1001/jama.2020.10245',
'journal-title': 'JAMA'},
{ 'key': 'ref29',
'unstructured': 'U.S. Food and Drug Administration. Coronavirus (COVID-19) update. FDA '
'authorizes monoclonal antibody for treatment of COVID-19. (2020). '
'Accessed: November 10, 2020: '
'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-tr....'},
{ 'key': 'ref30',
'unstructured': 'U.S. Food and Drug Administration. Coronavirus (COVID-19) update. FDA '
'authorizes monoclonal antibody for treatment of COVID-19. (2021). '
'Accessed: April 17, 2021: '
'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorizati....'}],
'container-title': 'Cureus',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.cureus.com/articles/58640-clinical-impact-of-the-early-use-of-monoclonal-antibody-ly-cov555-bamlanivimab-on-mortality-and-hospitalization-among-elderly-nursing-home-patients-a-multicenter-retrospective-study',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 2, 9]],
'date-time': '2024-02-09T19:26:10Z',
'timestamp': 1707506770000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/58640-clinical-impact-of-the-early-use-of-monoclonal-antibody-ly-cov555-bamlanivimab-on-mortality-and-hospitalization-among-elderly-nursing-home-patients-a-multicenter-retrospective-study'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 5, 10]]},
'references-count': 30,
'URL': 'http://dx.doi.org/10.7759/cureus.14933',
'relation': {},
'ISSN': ['2168-8184'],
'subject': ['Aerospace Engineering'],
'published': {'date-parts': [[2021, 5, 10]]}}
